You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
【華泰醫藥代雯團隊】天境生物:聯手國控,全面推進商業化建設
格隆匯 10-27 18:04

10月25日,天境生物宣佈與國藥控股(1099.HK)達成協議,雙方就分銷、重點項目等方面開展全方位合作,同時宣佈CD38單抗菲澤妥單抗計劃4Q21提交BLA。

供應鏈全方位合作

公司與國控將在產品准入、進口、倉儲、物流等方面長期緊密合作,並授權國藥控股集團內300多家子公司作為分銷商,進行零售調撥及終端銷售。雙方將就重點項目等方面開展全方位合作,合力推動高度差異化、BIC乃至FIC產品儘快進入國內市場。

商業化體系建設起步,邁向“天境2.0”

我們認為公司和國控的合作將持續推動公司向“天境2.0”時代發展:1)隨着菲澤妥單抗等品種陸續進入BLA階段,公司的商業化能力逐步展開建設,國控作為國內最大的藥品批發商和零售商,其藥品准入能力和政府事務能力有助於加速公司產品的市場推廣;2)國控是國內GSP標準的領導者,我們預計天境將在國控的助力下推進高標準GSP公司的建設,打造領銜國內biotech的供應鏈體系,初步形成綜合性biopharma。

管線迎來收穫季

公司獨具特色的差異化管線持續取得進展:1)菲澤妥單抗的三線MM適應症有望於4Q21提交BLA,同時二線MM適應症已完成全部患者入組;CD47單抗來佐利單抗將於年底ASH披露NHL的II期臨牀數據,並有望於4Q21完成聯合阿扎胞苷治療AML/MDS的國內臨牀的患者招募;2)早期創新管線中TJ-CD4B和TJ-L14B均將於SITC年會發布臨牀前數據。我們認為公司管線正處於持續收穫的階段,未來半年內有望持續迎來催化劑兑現。

聯繫人:代雯/袁中平

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account